NCT07909733
Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT
StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Maximum tolerated dose (MTD) of imetelstat
Timeframe: 1 year
Secondary (5)
Incidence of adverse events
Rate of non-relapse mortality (NRM)
Rate of relapse
Progression-free survival (PFS)
Overall survival (OS)
Arms and interventions
Dose escalationExperimental
Participants will receive imetelstat intravenously every 4 weeks with dose escalation.
Drugs: imetelstat
Sites
1 site in 1 country
- University of Wisconsin - MadisonMadison, Wisconsin, United States